... biosimilars will change the clinical use of biologics. Biosimilars Infliximab Inflammatory bowel disease Crohns disease Ulcerative colitis Health economics Biosimilars are drugs that are intended to be equivalent to the original product in terms of efficacy, adverse reactions, immunogenicity...

... with moderate to severe disease activity. After 14 weeks of treatment there was a significant reduction in the Harvey Bradshaw index in patients with Crohns disease (CD) and reduction in the partial Mayo score and simple clinical colitis activity index in patients with ulcerative colitis. In both patient groups...